- Previous Close
1,528.55 - Open
1,529.95 - Bid --
- Ask --
- Day's Range
1,503.55 - 1,533.90 - 52 Week Range
1,041.00 - 1,708.65 - Volume
530,951 - Avg. Volume
425,637 - Market Cap (intraday)
383.854B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
61.86 - EPS (TTM)
24.46 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield 4.00 (0.26%)
- Ex-Dividend Date Nov 25, 2024
- 1y Target Est
1,551.28
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
www.ipca.com17,335
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: IPCALAB.NS
View MorePerformance Overview: IPCALAB.NS
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPCALAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPCALAB.NS
View MoreValuation Measures
Market Cap
387.51B
Enterprise Value
390.08B
Trailing P/E
62.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.85
Price/Book (mrq)
5.79
Enterprise Value/Revenue
4.62
Enterprise Value/EBITDA
25.90
Financial Highlights
Profitability and Income Statement
Profit Margin
7.02%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
82.13B
Net Income Avi to Common (ttm)
5.77B
Diluted EPS (ttm)
24.46
Balance Sheet and Cash Flow
Total Cash (mrq)
8.54B
Total Debt/Equity (mrq)
18.61%
Levered Free Cash Flow (ttm)
--